Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract
SummaryThree important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of systemic therapies in respective patients are discussed. Enfortumab vedotin, an antibody-drug conjugate targeting nectin ‑4, demonstrated a clinically meaningful objective response rate in patients with prior platinum-based chemotherapy and checkpoint inhibition, in a phase II trial. A high unmet need in this heavily pretreated patient population combined with good tolerability and manageable safety profile supp ort a submission to the FDA (US Food and Drug Administration) for accelerated approval. The early use of an immunotherapeutic approach via pembrolizumab in patients with metastatic urothelial carcinoma as “switch maintenance” therapy achieved an objective response rate of 22% vs. 12% in the pla cebo arm in a phase II trial. Pembrolizumab was shown to potentially “deepen” responses achieved with first-line chemotherapy. Moreover, switch maintenance pembrolizumab was able to significantly delay disease progression, whereby a better characterized role of switch maintenance programmed d eath‑1 blockade will be refined by currently ongoing phase III trials. Based on data showing that angiogenesis plays an important role in urothelial carcinoma growth and p...
ConclusionsThis patient was diagnosed as having accessory breast cancer which presented with a subcutaneous mass. As this condition is exceptionally rare but curable by early treatments, we recommend surgeons to consider potential malignancy when patients present with a subcutaneous mass.
AbstractBackgroundPoor oral health is an independent risk factor for upper aerodigestive tract cancers, including esophageal squamous cell carcinoma (ESCC). The pattern recognition receptor Toll-like receptor 4 (TLR4) recognizes lipopolysaccharide in the cell walls of Gram-negative periodontal pathogens associated with the development and progression of ESCC. It is, therefore, plausible that TLR4 plays a crucial role in the pathogenesis of ESCC.MethodsWe used an ESCC tissue microarray to confirm expression of TLR4 in patients with ESCC and to determine whether TLR4 expression status correlates with the clinicopathological ...
The aim of this ongoing study was to examine Quality of Life (QoL) and pain in the first three months after trans-oral robotic surgery (TORS). Results will be available in November 2019. With the rising incidence of Human Papilloma Virus (HPV) induced oropharyngeal squamous cell carcinoma (OPSCC) this cancer has become the most frequently diagnosed head and neck cancer world-wide. Currently there are two main treatment options: radiotherapy (with or without chemotherapy) and TORS. TORS is still a relatively new treatment modality (approved by the FDA in 2000) and more research into outcomes, particularly functional and QoL outcomes is needed.
We describe a novel approach for chemoresistance profiling (CRP) in real time in HNSCC using peripheral blood Circulating-Tumor Associated Cells (CTACs). C-TACs are defined as apoptosis-resistant cells of tumorigenic origin which are positive for Epithelial Cell Adhesion Molecule (EpCAM) and pan-cytokeratins (pan-CK) irrespective of CD45 status.
Extranodal extension (ENE) in lymphatic metastases from oral cavity squamous cell carcinoma is an adverse prognostic feature that portends a poor prognosis and adverse outcomes. In a pooled analysis of two randomized controlled trials, a therapeutic benefit with the addition of chemotherapy to adjuvant radiotherapy was demonstrated in patients with ENE. The College of American Pathologists have recently recommended classification of ENE by extent of capsular invasion into minor (2mm) ENE.
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications....
Conclusions The mini-OPD regimen is an inexpensive, non-toxic and effective regimen for the prevention of CINV in patients receiving weekly cisplatin concurrent with pelvic radiotherapy.
Squamous cell carcinoma (SCC) of the tongue is the most common oral cancer. Because of the tongue ’s frequent movement, abundant lymphatic drainage, and rich blood supply, the SCC is prone to regional lymph nodes and distant metastases, and its prognosis is worse than that of the other oral cancers.1 In addition, because of its special location, it and its secondary tissue defect postperativel y may impair the patient’s pronunciation and swallowing. Reliable and stable therapeutic targets can improve the curative effect and reduce the toxic side effects caused by surgery, radiotherapy, and chemotherapy.
Conclusion: In this study, the combination of Nimotuzumab plus platinum/taxane based chemotherapy was active and well tolerated in Indian patients in R/M SCCHN. Addition of Nimotuzumab to chemotherapy had a response rate of 38.2% and median PFS of 5.2 months are strong arguments for clinically testing this combination.